data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzdoNTEydjM0MS4zMjZIMHoiLz48cGF0aCBmaWxsPSIjRkY5ODExIiBkPSJNMCA4NS4zMzdoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjNkRBNTQ0IiBkPSJNMCAzMTIuODg4aDUxMnYxMTMuNzc1SDB6Ii8+PGNpcmNsZSBmaWxsPSIjMDA1MkI0IiBjeD0iMjU2IiBjeT0iMjU2IiByPSI0My44OTYiLz48Y2lyY2xlIGZpbGw9IiNGRkYiIGN4PSIyNTYiIGN5PSIyNTYiIHI9IjI3LjQzNCIvPjxwYXRoIGZpbGw9IiMwMDUyQjQiIGQ9Ik0yNTYgMjIyLjE0Nmw4LjQ2NCAxOS4xOTUgMjAuODU1LTIuMjY4TDI3Mi45MjcgMjU2bDEyLjM5MiAxNi45MjctMjAuODU1LTIuMjY4TDI1NiAyODkuODU0bC04LjQ2NC0xOS4xOTUtMjAuODU1IDIuMjY4TDIzOS4wNzMgMjU2bC0xMi4zOTItMTYuOTI3IDIwLjg1NSAyLjI2OHoiLz48L3N2Zz4=

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Mindset Pharma Inc Ordinary Shares

(OTC:MSSTF)

Intraday

$0.5381

0[0.00%]

15 minutes delayed

Perks Buy Compare Brokers

$0.5381

0[0.00%]

Last update: 3:55PM Get Real Time Here

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Mindset Pharma Inc Ordinary Shares Stock (OTC:MSSTF)

Mindset Pharma Inc Ordinary Shares Stock (OTC: MSSTF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, September 18, 2023

Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
Lara Goldstein - Sep 18, 2023, 4:30PM

Tuesday, September 05, 2023

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Lara Goldstein - Sep 5, 2023, 10:07AM

Thursday, August 31, 2023

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Lara Goldstein - Aug 31, 2023, 1:54PM

Tuesday, July 18, 2023

Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application
Lara Goldstein - Jul 18, 2023, 8:47PM

Monday, July 17, 2023

Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Lara Goldstein - Jul 17, 2023, 5:04PM

Tuesday, July 04, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein - Jul 4, 2023, 10:21AM

Thursday, June 29, 2023

Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Lara Goldstein - Jun 29, 2023, 1:22PM

Tuesday, June 27, 2023

UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
Lara Goldstein - Jun 27, 2023, 3:54PM

Monday, May 01, 2023

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein - May 1, 2023, 7:06PM

Wednesday, April 26, 2023

This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
Lara Goldstein - Apr 26, 2023, 2:52PM

Tuesday, April 25, 2023

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Lara Goldstein - Apr 25, 2023, 1:30PM

Thursday, March 23, 2023

HC Wainwright & Co. Reiterates Buy on Mindset Pharma, Maintains $5 Price Target
Benzinga Newsdesk - Mar 23, 2023, 6:23AM

Monday, March 20, 2023

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Lara Goldstein - Mar 20, 2023, 5:11PM

Tuesday, March 14, 2023

Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Lara Goldstein - Mar 14, 2023, 2:24PM

Monday, March 13, 2023

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Lara Goldstein - Mar 13, 2023, 5:13PM

Monday, March 06, 2023

Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
Lara Goldstein - Mar 6, 2023, 1:14PM

Friday, February 03, 2023

Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Lara Goldstein - Feb 3, 2023, 4:38PM

Wednesday, January 25, 2023

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Lara Goldstein - Jan 25, 2023, 12:02PM

Saturday, January 21, 2023

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Lara Goldstein - Jan 21, 2023, 2:52PM

Monday, November 21, 2022

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein - Nov 21, 2022, 7:13PM

Wednesday, November 16, 2022

These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
Lara Goldstein - Nov 16, 2022, 11:16AM

Monday, November 07, 2022

EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
Lara Goldstein - Nov 7, 2022, 10:35AM

Tuesday, October 11, 2022

European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
Lara Goldstein - Oct 11, 2022, 5:07PM

Friday, October 07, 2022

Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Lara Goldstein - Oct 7, 2022, 5:13PM
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Lara Goldstein - Oct 7, 2022, 9:21AM

Tuesday, September 27, 2022

Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Lara Goldstein - Sep 27, 2022, 2:20PM
Cybin Obtains Exclusive License To A Novel Catalog Of Psychedelic-Based Compounds
Benzinga Newsdesk - Sep 27, 2022, 8:07AM

Wednesday, September 14, 2022

Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Lara Goldstein - Sep 14, 2022, 2:26PM

Wednesday, September 07, 2022

Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Lara Goldstein - Sep 7, 2022, 6:43PM
Psychedelic Stock Gainers And Losers From September 7, 2022
Benzinga Insights - Sep 7, 2022, 4:40PM

Tuesday, September 06, 2022

Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
Viridian Capital Advisors - Sep 6, 2022, 11:25AM

Friday, September 02, 2022

Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today
Benzinga Insights - Sep 2, 2022, 5:16PM

Wednesday, August 31, 2022

This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Lara Goldstein - Aug 31, 2022, 4:41PM

Thursday, June 30, 2022

Intranasal Psychedelics Platform Is Here, Check Out Mindset's New Development
Lara Goldstein - Jun 30, 2022, 9:04AM

Wednesday, June 22, 2022

Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014
Lara Goldstein - Jun 22, 2022, 3:56PM

Wednesday, June 15, 2022

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Natan Ponieman - Jun 15, 2022, 12:32PM

Friday, June 10, 2022

Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders
Lara Goldstein - Jun 10, 2022, 11:49PM

Friday, April 08, 2022

Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 8, 2022, 5:16PM

Thursday, April 07, 2022

Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 7, 2022, 4:31PM

Wednesday, April 06, 2022

Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 6, 2022, 5:19PM

Tuesday, April 05, 2022

Psychedelic Stock Gainers And Losers From April 5, 2022
Benzinga Insights - Apr 5, 2022, 4:33PM

Monday, April 04, 2022

Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 4, 2022, 4:45PM

Friday, April 01, 2022

Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Benzinga Insights - Apr 1, 2022, 4:33PM

Thursday, March 31, 2022

Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 31, 2022, 4:33PM

Wednesday, March 30, 2022

Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 30, 2022, 4:52PM

Tuesday, March 29, 2022

Psychedelic Stock Gainers And Losers From March 29, 2022
Benzinga Insights - Mar 29, 2022, 5:03PM

Monday, March 28, 2022

Mindset Pharma, Small Pharma Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 28, 2022, 4:30PM

Friday, March 25, 2022

Psychedelic Stock Gainers And Losers From March 25, 2022
Benzinga Insights - Mar 25, 2022, 4:34PM

Thursday, March 24, 2022

Allied, Field Trip Health Among Top Psychedelic Movers Of Today
Benzinga Insights - Mar 24, 2022, 4:30PM
Is Wall Street The Next Stop For Psychedelics? Investing In The Psychedelic Medicine Sector
Psychedelic Spotlight - Mar 24, 2022, 2:39PM

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved